Large Australian Study could end deadly TB epidemic

The Centenary Institute and the University of Technology Sydney will lead pioneering research into age-related muscle loss, called sarcopenia, with a Dynamic Resilience Program contract from Wellcome Leap.

Researchers have discovered a new way to treat hepatocellular carcinoma (HCC), the most common type of liver cancer and the third leading cause of cancer death worldwide.

Dr Bobby Boumelhem, a dedicated researcher at the Centenary Institute, is on a mission to enhance the quality of life for individuals grappling with liver disease. Diseases such as hepatitis, liver cancer, non-alcoholic fatty liver disease and cirrhosis pose significant health challenges.

Researchers, including Dr Matt Johansen from the Centenary UTS Centre for Inflammation and Professor Phil Hansbro, Director of the Centenary UTS Centre for Inflammation, have discovered that a cancer drug could play an important role in limiting the damaging effects of lung disease in COVID-19 patients.